Karachi: In an update relevant to market participants and stakeholders, the Pakistan Stock Exchange (PSX) has announced a revised trading and settlement schedule for the deliverable future contracts of GlaxoSmithKline Pakistan Limited. The adjustment comes in response to the company's declaration of book closure dates. The precise changes pertain to the DFC-SEP-26 and DFC-OCT-26 contracts, which were initially communicated through notices PSX/N-779 on June 24, 2026, and PSX/N-956 on July 31, 2026.

According to the revised schedule, for the SEP contract, trading commenced on June 29, 2026, a Monday, and will close on August 31, 2026, which also falls on a Monday. The settlement for this contract is set for September 1, 2026, a Tuesday. Similarly, the OCT contract opened on August 3, 2026, a Monday, with the same closing and settlement dates as the SEP contract.

Furthermore, the trading and settlement timeline without the entitlement of benefits reflects additional adjustments. The SEPB contract opened on August 27, 2026, a Thursday, and will conclude on September 25, 2026, a Friday, with settlement on September 28, 2026, a Monday. The OCTB contract follows suit, opening on the same August date but extending its closing to October 30, 2026, a Friday, with settlement on November 2, 2026, a Monday.

The designated market category for these contracts remains consistent with the standard operational framework. According to information available from the Pakistan Stock Exchange (PSX), these modifications are essential to align with the corporate actions of GlaxoSmithKline Pakistan Limited, ensuring a seamless transition during the book closure period.